Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety Study of GSK Biologicals Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral (2013-2014 Season) in Adults Aged 18 Years and Older

Next Previous
X
Search
Trial Profile

Immunogenicity and Safety Study of GSK Biologicals Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral (2013-2014 Season) in Adults Aged 18 Years and Older

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 1536489A (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 08 Jan 2015 Protocol has been amended in treatment table from 1 arm to 2 arms, addition of primary endpoints , change of trial focus from 'PD' to TU & PD' and change of intervention model from single group to parallel assignment.
    • 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top